Another NRF2 inhibitor, halofuginone was shown to decrease Nrf2 at the protein level, through suppression prolyl-tRNA synthetase activity, and sensitize the chemotherapy on NRF2-addicted cancer cells 119. Here, NFE2L2 is linked to cancer.